CLL Updates From the 2019 ASH Annual Meeting

[Jm954]

Dr Anthony Mato, from New York - his take on a few pertinent questions relating to CLL such as

What data in chronic lymphocytic leukemia (CLL) that came out of the American Society of Hematology (ASH) 2019 meeting were considered practice changing?

What novel treatments for CLL that were highlighted during the meeting seem most promising?

Combination ibrutinib plus venetoclax: Is undetectable minimal residual disease (MRD) a good surrogate endpoint for survival? Why or why not?

and more interesting insights here - cancertherapyadvisor.com/ho...

Jackie

[AussieNeil Administrator]

Great questions with thoughtful responses, nicely provided as a transcript .

I consider this post worthy of pinning, given it is a leading CLL specialist's summary of what ASH 2019 presentations could change treatment practices.

Thanks,

Neil

[Smakwater in reply to AussieNeil]

Definitely a clear and concise summary presented in a way that is easily understood.

[Zia2]

Thanks Jackie. Much appreciated !